Kazuro Ikawa

Last Updated :2025/01/15

Affiliations, Positions
Hiroshima University Hospital(Department of Pharmaceutical Services), Professor (Special Recognition)
E-mail
ikawakhiroshima-u.ac.jp

Basic Information

Academic Degrees

  • Ph.D. (Pharmaceutical Sciences), The University of Tokushima
  • Master of Pharmaceutical Science, The University of Tokushima

Research Fields

  • Medicine,dentistry, and pharmacy;Boundary medicine;Applied pharmacology

Research Keywords

  • drug informatics
  • therapeutic drug monitoring
  • clinical pharmacometrics

Educational Activity

Course in Charge

  1. 2024, Undergraduate Education, First Semester, Research Practice A
  2. 2024, Undergraduate Education, Second Semester, Research Practice B
  3. 2024, Undergraduate Education, 1Term, Clinical Medicine and Pharmacotherapy I
  4. 2024, Undergraduate Education, 3Term, Drug Informatics
  5. 2024, Undergraduate Education, 1Term, Pharmacoeconomics
  6. 2024, Undergraduate Education, 3Term, Clinical Evaluation
  7. 2024, Undergraduate Education, 3Term, Japanese Pharmacopoeia
  8. 2024, Undergraduate Education, Year, Special laboratory Works in Pharmaceutical Sciences I
  9. 2024, Undergraduate Education, Year, Special laboratory Works in Pharmaceutical Sciences II
  10. 2024, Undergraduate Education, Second Semester, Special laboratory Works in Pharmaceutical Sciences III
  11. 2024, Undergraduate Education, Year, Special laboratory Works in Clinical Pharmacy I
  12. 2024, Undergraduate Education, Year, Special laboratory Works in Clinical Pharmacy II
  13. 2024, Undergraduate Education, Year, Special laboratory Works in Clinical Pharmacy III
  14. 2024, Graduate Education (Doctoral Program) , 4Term, Pharmacotherapeutic Research
  15. 2024, Graduate Education (Master's Program) , First Semester, Seminar on Pharmacotherapy Informatics
  16. 2024, Graduate Education (Master's Program) , Second Semester, Seminar on Pharmacotherapy Informatics

Research Activities

Academic Papers

  1. Risk Factors for Ganciclovir-Induced Thrombocytopenia and Leukopenia, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 38(2), 235-238, 201502
  2. Linezolid dosage in pediatric patients based on pharmacokinetics and pharmacodynamics, JOURNAL OF INFECTION AND CHEMOTHERAPY, 21(1-2), 70-73, 2015
    Link to Paper Search Results by DOI
  3. Population pharmacokinetic-pharmacodynamic target attainment analysis of sulbactam in patients with impaired renal function: Dosing considerations for Acinetobacter baumannii infections, JOURNAL OF INFECTION AND CHEMOTHERAPY, 21(3-4), 284-289, 2015
    Link to Paper Search Results by DOI
  4. Evaluation of a pharmacokinetic-pharmacodynamic approach using software to optimize the carbapenem antibiotic regimen, INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 53(6), 422-429, 201506
    Link to Paper Search Results by DOI
  5. Pharmacokinetics and dosing estimation of meropenem in Japanese patients receiving continuous venovenous hemodialysis, JOURNAL OF INFECTION AND CHEMOTHERAPY, 21(5-6), 476-478, 2015
    Link to Paper Search Results by DOI
  6. Mechanisms of Fatal Cardiotoxicity following High-Dose Cyclophosphamide Therapy and a Method for Its Prevention, PLOS ONE, 10(6), 20150626
    Link to Paper Search Results by DOI
  7. Penetration of piperacillin-tazobactam into human prostate tissue and dosing considerations for prostatitis based on site-specific pharmacokinetics and pharmacodynamics, JOURNAL OF INFECTION AND CHEMOTHERAPY, 21(8), 575-580, 201508
    Link to Paper Search Results by DOI
  8. Pharmacokinetics of Prophylactic Ampicillin Sulbactam and Dosing Optimization in Patients Undergoing Cardiovascular Surgery with Cardiopulmonary Bypass, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 38(11), 1817-1821, 201511
  9. Trough level monitoring of intravenous busulfan to estimate the area under the plasma drug concentration-time curve in pediatric hematopoietic stem cell transplant recipients, INTERNATIONAL JOURNAL OF HEMATOLOGY, 102(5), 611-616, 201511
    Link to Paper Search Results by DOI
  10. Lafutidine, a newly developed antiulcer drug, elevates postprandial intragastric pH and increases plasma calcitonin gene-related peptide and somatostatin concentrations in humans: comparisons with famotidine., Digestive diseases and sciences, 51(1), 2006
  11. A simple and rapid determination of biapenem in plasma by high-performance liquid chromatography., Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 844(1), 2006
  12. The pharmacokinetics of low-dose thalidomide in Japanese patients with refractory multiple myeloma., Biological & pharmaceutical bulletin, 29(11), 2006
  13. Which has superior acid-suppressive effect, 10 mg omeprazole once daily or 20 mg famotidine twice daily? Effects of single or repeated administration in Japanese Helicobacter pylori-negative CYP2C19 extensive metabolizers., Digestive diseases and sciences, 52(2), 2007
  14. Pharmacokinetic and pharmacodynamic properties of lafutidine after postprandial oral administration in healthy subjects: comparison with famotidine., Biological & pharmaceutical bulletin, 30(5), 2007
  15. High-performance liquid chromatography with ultraviolet detection for real-time therapeutic drug monitoring of meropenem in plasma., Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 856(1-2), 2007
  16. Pharmacokinetic and pharmacodynamic profiling of cefepime in plasma and peritoneal fluid of abdominal surgery patients., International journal of antimicrobial agents, 30(3), 2007
  17. Peritoneal penetration and pharmacodynamic exposure of intravenous cefozopran in abdominal surgery patients., International journal of antimicrobial agents, 30(4), 2007
  18. Real-time therapeutic drug monitoring of cefozopran in plasma using high-performance liquid chromatography with ultraviolet detection., Journal of pharmaceutical and biomedical analysis, 45(5), 2007
  19. Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients., The Journal of antimicrobial chemotherapy, 60(6), 2007
  20. Pharmacokinetic modeling and dosage adaptation of biapenem in Japanese patients during continuous venovenous hemodiafiltration., Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 14(1), 2008
  21. Quantification of doripenem in human plasma and peritoneal fluid by high-performance liquid chromatography with ultraviolet detection., Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 867(1), 2008
  22. Pharmacodynamic evaluation of biapenem in peritoneal fluid using population pharmacokinetic modelling and Monte Carlo simulation., International journal of antimicrobial agents, 32(4), 2008
  23. Peritoneal pharmacokinetics of cefepime in laparotomy patients with inflammatory bowel disease, and dosage considerations for surgical intra-abdominal infections based on pharmacodynamic assessment., Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 14(2), 2008
  24. Pharmacokinetic-pharmacodynamic target attainment analysis of cefozopran in Japanese adult patients., Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 14(2), 2008
  25. Development of breakpoints of cephems for intraabdominal infections based on pharmacokinetics and pharmacodynamics in the peritoneal fluid of patients., Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 14(2), 2008
  26. Penetration into and exposure of cefozopran in pelvic retroperitoneal space exudate., Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 14(2), 2008
  27. Pharmacodynamic assessment of doripenem in peritoneal fluid against Gram-negative organisms: use of population pharmacokinetic modeling and Monte Carlo simulation., Diagnostic microbiology and infectious disease, 62(3), 2008
  28. Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients., International journal of antimicrobial agents, 33(3), 2009
  29. Determination of total cefozopran concentrations in human peritoneal fluid by HPLC with cefepime as an internal standard: Comparative pharmacokinetics in the fluid and plasma., Journal of pharmaceutical and biomedical analysis, 49(4), 2009
  30. [Dosing regimen rationalization of biapenem in pediatric patients: use of Monte Carlo simulation]., The Japanese journal of antibiotics, 62(1), 2009
  31. [Personalized optimization of beta-lactam regimens based on studies of the pharmacokinetics-pharmacodynamics at the target sites]., [Personalized optimization of beta-lactam regimens based on studies of the pharmacokinetics-pharmacodynamics at the target sites]., 129(7), 2009
  32. Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections., The Journal of antimicrobial chemotherapy, 64(4), 2009
  33. Pharmacokinetics and pharmacodynamics of once-daily arbekacin during continuous venovenous hemodiafiltration in critically ill patients., Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 15(6), 2009
  34. Population pharmacokinetic modeling and pharmacodynamic assessment of cefozopran in pediatric patients., The Japanese journal of antibiotics, 62(5), 2009
  35. Pharmacokinetic–pharmacodynamic target attainment analysis of meropenem in Japanese adult patients., Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 16(1), 2010
  36. Population pharmacokinetics and pharmacodynamics of meropenem in Japanese pediatric patients., Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 16(2), 2010
  37. HPLC method for measuring meropenem and biapenem concentrations in human peritoneal fluid and bile: application to comparative pharmacokinetic investigations., Journal of chromatographic science, 48(5)
  38. Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment., Antimicrobial agents and chemotherapy, 55(12), 2011
  39. Development and validation of a GC-EI-MS method with reduced adsorption loss for the quantification of olanzapine in human plasma., Analytical and bioanalytical chemistry, 403(7), 2012
  40. Optimisation of imipenem regimens in patients with impaired renal function by pharmacokinetic-pharmacodynamic target attainment analysis of plasma and urinary concentration data., International journal of antimicrobial agents, 40(5), 2012
  41. Penetration of meropenem into human pancreatic juice., Scandinavian journal of infectious diseases, 45(5), 2013
  42. Population pharmacokinetic-pharmacodynamic target attainment analysis of imipenem plasma and urine data in neonates and children., The Pediatric infectious disease journal, 32(11), 2013
  43. Clinical pharmacokinetics of meropenem in pancreatic juice and site-specific pharmacodynamic target attainment against Gram-negative bacteria: dosing considerations., Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 14(2)
  44. Pharmacokinetic/pharmacodynamic evaluation of sulbactam against Acinetobacter baumannii in in vitro and murine thigh and lung infection models., International journal of antimicrobial agents, 43(6), 2014
  45. Gas chromatography-electron ionization-mass spectrometry quantitation of valproic acid and gabapentin, using dried plasma spots, for therapeutic drug monitoring in in-home medical care., Biomedical chromatography : BMC, 28(12), 2014
  46. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients., International journal of antimicrobial agents, 44(3), 2014
  47. Linezolid dosage in pediatric patients based on pharmacokinetics and pharmacodynamics., Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 21(1), 2015
  48. Population pharmacokinetic-pharmacodynamic target attainment analysis of sulbactam in patients with impaired renal function: dosing considerations for Acinetobacter baumannii infections., Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 21(4), 2015
  49. Pharmacokinetics and dosing estimation of meropenem in Japanese patients receiving continuous venovenous hemodialysis., Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 21(6), 2015
  50. Penetration of piperacillin-tazobactam into human prostate tissue and dosing considerations for prostatitis based on site-specific pharmacokinetics and pharmacodynamics., Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 21(8), 2015
  51. Pharmacokinetics and skin-tissue penetration of daptomycin in rats., Clinical pharmacology : advances and applications, 7, 2015
  52. Pharmacokinetics and pharmacodynamic assessment of imipenem in the intraperitoneal fluid of abdominal surgery patients., Chemotherapy, 54(2), 2008
  53. Development of breakpoints of carbapenems for intraabdominal infections based on pharmacokinetics and pharmacodynamics in peritoneal fluid., Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 14(4), 2008
  54. Pharmacokinetic-pharmacodynamic target attainment analysis of biapenem in adult patients: a dosing strategy., Chemotherapy, 54(5), 2008
  55. Continuous ampicillin infusion as an alternative to intermittent infusion for adult inpatients: a case series., Continuous ampicillin infusion as an alternative to intermittent infusion for adult inpatients: a case series., 20(10), 2014